Decitabine/cedazuridine

Decitabine/cedazuridine, sold under the brand name Inqovi, is a fixed-dose combination anticancer medication used to treat myelodysplastic syndromes and chronic myelomonocytic leukemia in adults. Decitabine is a nucleoside metabolic inhibitor that disrupts the growth of abnormal blood cells, and cedazuridine is a cytidine deaminase inhibitor that protects decitabine from being broken down in the gut, allowing the combination to be taken as an oral tablet rather than by injection. Myelodysplastic syndromes are a group of blood cancers in which the bone marrow produces defective blood cells, leading to low counts of one or more blood cell types. The United States Food and Drug Administration approved the combination in July 2020, and the European Union approved it in September 2023. It is marketed by Astex Pharmaceuticals, Inc., a subsidiary of Otsuka Pharmaceutical Co. Ltd.